Mucosal vaccination approach against mosquito-borne Japanese encephalitis virus

Japanese Journal of Infectious Diseases

Volumn 62, Issue 1, 2009, Pages 37-45

  Harakumi, Tetsuya ^a,b   Kohama, Hideyasu ^b   Tadano, Masyuki ^b   Uechi, Gen Ichiro ^b,f   Tsuji, Naotoshi ^c   Matsumoto, Yasunobu ^d   Miyata, Takeshi ^b   Tsuboi, Takafumi ^e   Oku, Hirosuke ^a   Arakawa, Takeshi ^b  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

^c NATIONAL INSTITUTE OF ANIMAL HEALTH   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e EHIME UNIVERSITY   (Japan)

^f NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; CHOLERA TOXIN; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; JAPANESE ENCEPHALITIS VACCINE; PERTUSSIS TOXIN; PERTUSSIS VACCINE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BLOODBORNE BACTERIUM; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG POTENTIATION; FEASIBILITY STUDY; IMMUNIZATION; IMMUNOGENICITY; JAPANESE ENCEPHALITIS VIRUS; MOSQUITO; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; VACCINATION; VIRUS ENVELOPE; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC ENCEPHALITIS; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; NOSE MUCOSA; SERODIAGNOSIS; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; CHOLERA TOXIN; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; IMMUNIZATION, SECONDARY; JAPANESE ENCEPHALITIS VACCINES; MICE; MICE, INBRED BALB C; NASAL MUCOSA; NEUTRALIZATION TESTS; PERTUSSIS TOXIN; RECOMBINANT PROTEINS; VACCINATION;

EID: 63149135013     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Tadano, M., Kanemura, K., Hasegawa, H., et al. (1994): Epidemiological and ecological studies of Japanese encephalitis in Okinawa, subtropical area in Japan. I. Investigations on antibody levels to Japanese encephalitis virus in swine sera and mosquito in Okinawa, Miyako and Ishigaki islands. Microbiol. Immunol., 38, 117-122.
2. Bharati, K. and Vrati, S. (2006): Japanese encephalitis: development of new candidate vaccines. Expert. Rev. Anti. Infect. Ther., 4, 313-324.
3. Kaur, R. and Vrati, S. (2003): Development of a recombinant vaccine against Japanese encephalitis. J. Neurovirol., 9, 421-431.
4. Monath, T.-P., McCarthy, K., Bedford, P., et al. (2002): Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine, 20, 1004-1018.
5. Monath, T.-P., Guirakhoo, F., Nichols, R., et al. (2003): Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis., 188, 1213-1230.
6. Srivastava, A.-K., Putnak, J.-R., Lee, S.-H., et al. (2001): A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine, 19, 4557-4565.
7. Zanin, M.-P., Webster, D.-E., Martin, J.-L., et al. (2003): Japanese encephalitis vaccines: moving away from the mouse brain. Expert. Rev. Vaccines, 2, 407-416.
8. Yuki, Y. and Kiyono, H. (2003): New generation of mucosal adjuvants for the induction of protective immunity. Rev. Med. Virol., 13, 293-310.
9. Haneberg, B. and Holst, J. (2002): Can nonliving nasal vaccines be made to work? Expert. Rev. Vaccines, 1, 227-232.
10. Harandi, A.-M., Sanchez, J., Eriksson, K., et al. (2003): Recent developments in mucosal immunomodulatory adjuvants. Curr. Opin. Investig. Drugs, 4, 156-161.
11. Bundo, K., Matsuo, S. and Igarashi, A. (1981): Enzyme-linked immunosorbent assay on Japanese encephalitis virus. II. Antibody levels in the patient sera. Trop. Med., 23, 135-148.
12. Igarashi, A. (1978): Isolation of a Singh's Aedes albopictus cell clone sensitive to dengue and chikungunya virus. J. Gen. Virol., 40, 531-544.
13. Okuno, Y., Fukunaga, T., Tadano, M., et al. (1985): Rapid focus reduction neutralization test of Japanese encephalitis virus in microtiter system. Arch. Virol., 86, 129-135.
14. Lesieur, C., Cliff, M.-J., Carter, R., et al. (2002): A kinetic model of intermediate formation during assembly of cholera toxin B-subunit pentamers. J. Biol. Chem., 277, 16697-16704.
15. Wu, K.-P., Wu, C.-W., Tsao, Y.-P., et al. (2003): Structural basis of a flavivirus recognized by its neutralizing antibody. J. Biol. Chem., 278, 46007-46013.
16. Kanai, R., Kar, K., Anthony, K., et al. (2006): Crystal structure of West Nile virus envelope glycoprotein reveals viral surface epitopes. J. Virol., 80, 11000-11008.
17. Lin, C.-W. and Wu, S.-C. (2003): A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites. J. Virol., 77, 2600-2606.
18. Kaslow, D.-C., Quakyi, I.-A., Syin, C., et al. (1988): A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature, 333, 74-76.
19. Kaslow, D.-C., Bathurst I.-C., Lensen, T., et al. (1994): Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect. Immun., 62, 5576-5580.
20. Eriksson, K. and Holmgren, J. (2002): Recent advances in mucosal vaccines and adjuvants. Curr. Opin. Immunol., 14, 666-672.
21. Holmgren, J., Czerkinsky, C., Eriksson, K., et al. (2003): Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine, 21 (Suppl. 2), S89-95.
22. Arakawa, T., Komesu, A., Otsuki, H., et al. (2005): Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect. Immun., 73, 7375-7380.
23. Cher, D.-J. and Mosmann, T.-R. (1987): Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by THI clones. J. Immunol., 138, 3688-3694.
24. Rauthan, M., Kaur, R., Appaiahgari M.-B., et al. (2004): Oral immunization of mice with Japanese encephalitis virus envelope protein synthesized in Escherichia coli induces anti-viral antibodies. Microbes Infect., 6, 1305-1311.
25. Kawamura, Y.-I., Kawashima, R., Shirai, Y., et al. (2003): Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated by NF-kappaB translocation. Eur. J. Immunol., 33, 3205-3212.
26. Eriksson, A. and Lycke, N. (2003): The CTA1-DD vaccine adjuvant binds to human B cells and potentiates their T cell stimulating ability. Vaccine, 22, 185-193.
27. Eriksson, K., Sun, J.-B., Nordstrom, I., et al. (2004): Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I-restricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor. Eur. J. Immunol., 34, 1272-1281.
28. George-Chandy, A., Eriksson, K., Lebens, M., et al. (2001): Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells. Infect. Immun., 69, 5716-5725.
29. Arrington, J., Braun, R.-P., Dong, L., et al. (2002): Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J. Virol., 76, 4536-4546.
30. Hagiwara, Y., Iwasaki, T., Asanuma, H., et al. (2001): Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain. Vaccine, 19, 1652-1660.
31. Fraser, S.-A., de Haan, L., Hearn, A.-R., et al. (2003): Mutant Escherichia coli heat-labile toxin B subunit that separates toxoid-mediated signaling and immunomodulatory action from trafficking and delivery functions. Infect. Immun., 71, 1527-1537.
32. Ohmura, M., Yamamoto, M., Kiyono, H., et al. (2001): Highly purified mutant E112K of cholera toxin elicits protective lung mucosal immunity to diphtheria toxin. Vaccine, 20, 756-762.
33. Yamamoto, S., Takeda, Y., Yamamoto, M., et al. (1997): Mutants in the ADP-ribosyltranferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med., 185, 1203-1210.
34. Nochi, T., Takagi, H., Yuki, Y., et al. (2007): Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc. Natl. Acad. Sci. USA, 104, 10986-10991.
35. Harakuni, T., Sugawa, H., Komesu, A., et al. (2005): Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems. Infect. Immun., 73, 5654-5665.
36. Goto, N., Maeyama, J., Yasuda, Y., et al. (2000): Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. Vaccine, 18, 2164-2171.
37. Lebens, M., Sun, J.-B., Sadeghi, H., et al. (2003): A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection. Vaccine, 21, 514-520.
38. Agren, L., Ekman, C.-L., Lowenadler, B., et al. (1997): Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin AI subunit. J. Immunol., 158, 3936-3946.
39. Boyle, J.-S., Brady, J.L. and Lew, A.-M. (1998): Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature, 392, 408-411.
40. Enioutina, E.-Y., Visic, D. and Daynes, R.-A. (2000): The induction of systemic and mucosal immune responses io antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine, 18, 2753-2767.
41. Eriksson, K., Fredriksson, M., Nordstrom, I., et al. (2003): Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development. Infect. Immun., 71, 1740-1747.
42. Niikura, M., Takamura, S., Kim, G., et al. (2002): Chimeric recombinant hepatitis E virus-hke particles as an oral vaccine vehicle presenting foreign epitopes. Virology, 293, 273-280.
43. van der Lubben, I.-M., Kersten, G., Fretz, M.-M., et al. (2003): Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine, 21, 1400-1408.
44. Watanabe, I., Ross, T.-M., Tamura, S., et al. (2003): Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin. Vaccine, 21, 4532-4538.
45. Wu, Y., Wang, X., Csencsits, K.-L., et al. (2001): M cell-targeted. DNA vaccination. Proc. Natl. Acad. Sci. USA, 98, 9318-9323.
46. Glenn, G.-M., Taylor, D.-N., Li, X., et al. (2000): Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med., 6, 1403-1406.
47. Glenn, G.-M., Scharton-Kersten, T., Vassell, R., et al. (1999): Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun., 67, 1100-1106.
48. Chen, D., Endres, R.-L., Erickson, C.-A., et al. (2000): Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat. Med., 6, 1187-1190.
49. Oya, A. (1988): Japanese encephalitis vaccine. Acta Paediatr. Jpn., 30, 175-184.